Stockreport

Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Asso...

Rocket Pharmaceuticals, Inc.  (RCKT) 
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: rocketpharma.com
PDF All six evaluable Phase 1 patients with Danon disease are alive and transplant-free up to age 25 yearsRP-A501 demonstrated safety and meaningful efficacy; all evaluable [Read more]